Get started
Author

Vladimir Cmiljanović

Observed names: Cmiljanovic, Vladimir, Cmiljanović, Vladimir, V. Cmiljanovic, Vladimir Cmiljanovic
OpenAlex ID: A5047417648
Targeting phosphoinositide 3-kinase—Moving towards therapy
2007 · Romina Marone, Vladimir Cmiljanovic, et al. · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · 548
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
2017 · Florent Beaufils, Natasa Cmiljanovic, et al. · Journal of Medicinal Chemistry · 142
Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
2009 · Romina Marone, Dominik Erhart, et al. · Molecular Cancer Research · 121
Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
2017 · Thomas Bohnacker, Andrea E. Prota, et al. · Nature Communications · 117
PDF
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
2017 · Chiara Tarantelli, Eugenio Gaudio, et al. · Clinical Cancer Research · 114
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
2018 · Andreas Wicki, Nicholas Brown, et al. · European Journal of Cancer · 65
PDF
A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications
2024 · Jacob Schön, G. Tuba Barut, et al. · Nature Microbiology · 27
PDF
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
2019 · Chiara Tarantelli, Eugenio Gaudio, et al. · Cancers · 16
PDF
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
2024 · Filip Janku, Grace M. Choong, et al. · Cancers · 14
PDF
High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamsters
2024 · Martin Joseph Lett, Fabian Otte, et al. · npj Vaccines · 7
PDF
Exon–Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation
2021 · Nicolas Munz, Luciano Cascione, et al. · Non-Coding RNA · 5
PDF
Abstract 4514: PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability
2015 · Vladimir Cmiljanovic, Robert A. Ettlin, et al. · Cancer Research · 5
Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype
2025 · Chiara Tarantelli, Omar Kayali, et al. · Hematological Oncology · 3
Abstract 159: Pharmacological characterization of the selective, orally bioavailable, potent dual PI3K/mTORC1/2 inhibitor PQR530
2017 · Petra Hillmann, Denise Rageot, et al. · Cancer Research · 3
Abstract 2664: PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor
2015 · Vladimir Cmiljanovic, Natasa Cmiljanovic, et al. · Cancer Research · 3
The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response
2014 · Chiara Tarantelli, Eugenio Gaudio, et al. · Blood · 2
The novel mTORC1/2 inhibitor PQR620 has in vitro and in vivo activity in lymphomas
2016 · C. Tarantelli, E. Gaudio, et al. · European Journal of Cancer · 1
The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas
2015 · Chiara Tarantelli, Eugenio Gaudio, et al. · Blood · 1
Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas
2015 · Chiara Tarantelli, Eugenio Gaudio, et al. · Cancer Research · 1
Abstract 671: BKM120-mediated G2 arrest: Structural and functional segregation of off-target action and PI3K inhibition
2015 · Thomas Bohnacker, Florent Beaufils, et al. · Cancer Research · 1
Author response for "Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype"
2025 · Chiara Tarantelli, Omar Kayali, et al.
Author response for "Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype"
2024 · Chiara Tarantelli, Omar Kayali, et al.
Promising Next-Generation SARS-CoV-2 Live Vaccine Demonstrates Remarkable Safety, Protection, and Immunity Profile in Pre-Clinical Studies
2024 · Schön, Jacob, Barut, G. Tuba, et al. · OpenAgrar
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
2024 · Janku, Filip; https://orcid.org/0000-0002-8123-4065, Choong, Grace M, et al. · Zurich Open Repository and Archive (University of Zurich)
Single-cycle SARS-CoV-2 vaccine elicits high protection and sterilizing immunity in hamsters
2023 · Thomas Klimkait, Martin Lett, et al. · Research Square
PDF
Works count: 61
Citation count: 1,196
H-index: 9
I10-index: 9
Year
Topic
Type